Pasithea Therapeutics

KTTA

Market cap $15.2M

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress' standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that an abstract detailing the Phase 1 dose-escalation study of PAS-004 in patients with MAPK pathway-driven advanced solid tumors has been accepted for poster presentation in the Developmental Therapeutics track at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, at the IFEMA Madrid Convention Center in Madrid, Spain. Details of the Poster Presentation: Title: Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors Presenter: Kartik Krishnan, Miami, Florida, United States Authors: Ildefonso I.

KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.

MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle & Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.

--  Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and gastrointestinal toxicities -- Protocol Amendment Extends Dose Escalation to Higher Levels: Continued dose escalation using tablet formulation to explore 18mg, 24mg, 30mg, 40mg, and up to 52mg dose levels to further characterize safety, pharmacokinetics (PK), and early efficacy signals at higher doses -- Potential Best-in-Class MEK Inhibitor Profile Emerging: Interim PK and safety data at pharmacologically active doses support PAS-004 as a differentiated candidate with potential for long-term chronic dosing with favorable tolerability -- Pilot Food Effect Study Initiated: An optional pilot food effect assessment has been introduced to evaluate the impact of fed vs. fasted administration on PAS-004 pharmacokinetics, to optimize long-term dosing strategy MIAMI, June 30, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced updated interim safety and clinical activity data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation, including patients who have failed prior BRAF/MEK inhibitor treatment (NCT06299839).

-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 (NF1) patients with symptomatic inoperable, incompletely resected, or recurrent plexiform neurofibroma (PN). The amendments include an update to the dose escalation part of the study (Part A) to allow for the enrollment of additional participants at two additional higher dose levels (24mg and 32mg), the ability to backfill completed dose cohorts (4mg, 8mg, 12mg and 18mg) with up to two participants, and the evaluation of intermediate dose levels.

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in advance to schedule – MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it will participate as an exhibitor in the upcoming Children's Tumor Foundation (CTF) 2026 NF Conference, held June 26-30, 2026, in Denver, Colorado. “Direct engagement with the clinical and academic NF1 community strengthens our commitment to develop better-tolerated therapies that can be used safely over the long term,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.

Pasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PAS-004 for the treatment of Amyotrophic Lateral Sclerosis (ALS). “ALS remains a devastating neurodegenerative disease with limited treatment options and significant unmet medical need,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026.

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.